The use of rodent models of glaucoma has been essential to understand the molecular mechanisms that underlie the pathophysiology of this multifactorial neurodegenerative disease. With the advent of numerous transgenic mouse lines, there is increasing interest in inducible murine models of ocular hypertension. Here, we present an occlusion model of glaucoma based on the injection of magnetic microbeads into the anterior chamber of the eye using a modified microneedle with a facetted bevel. The magnetic microbeads are attracted to the iridocorneal angle using a handheld magnet to block the drainage of aqueous humour from the anterior chamber. This disruption in aqueous dynamics results in a steady elevation of intraocular pressure, which subsequently leads to the loss of retinal ganglion cells, as observed in human glaucoma patients. The microbead occlusion model presented in this manuscript is simple compared to other inducible models of glaucoma and also highly effective and reproducible. Importantly, the modifications presented here minimize common issues that often arise in occlusion models. First, the use of a bevelled glass microneedle prevents backflow of microbeads and ensures that minimal damage occurs to the cornea during the injection, thus reducing injury-related effects. Second, the use of magnetic microbeads ensures the ability to attract most beads to the iridocorneal angle, effectively reducing the number of beads floating in the anterior chamber avoiding contact with other structures (e.g., iris, lens). Lastly, the use of a handheld magnet allows flexibility when handling the small mouse eye to efficiently direct the magnetic microbeads and ensure that there is little reflux of the microbeads from the eye when the microneedle is withdrawn. In summary, the microbead occlusion mouse model presented here is a powerful investigative tool to study neurodegenerative changes that occur during the onset and progression of glaucoma.
Introduction
Glaucoma is a progressive and irreversible blinding condition that will affect an estimated 80 million people worldwide by 2020 1 . In glaucoma patients, vision loss is caused by the selective death of retinal ganglion cells (RGCs), the output neurons that transmit visual information from the retina to the brain. Glaucoma is an age-related neurodegenerative disease with many risk factors of which the most common is elevated intraocular pressure (IOP). Indeed, IOP is the only modifiable risk factor in glaucoma and current treatments focus solely on managing eye pressure. However, multiple genetic, cellular, and environmental factors affect the onset and progression of this disease. Therefore, understanding the various mechanisms that ultimately contribute to neuronal death is essential to develop effective treatments for glaucoma.
Animal models of glaucoma are essential to study disease pathophysiology and to identify and test promising therapeutics. The increasing availability of transgenic mouse lines including conditional knockout strains and mice carrying genetically-encoded fluorescent tracers has propelled the need for inducible murine glaucoma models. Several rodent models of glaucoma have been developed over the years (reviewed in 2, 3 ). In many of these models, glaucoma is induced by disrupting aqueous humour dynamics, resulting in the elevation of IOP. Occlusion models, in which microbeads or other substances are injected into the anterior chamber of the eye to block aqueous drainage, have gained popularity in recent years partly due to their relative ease to increase IOP [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] .
The microbead occlusion model of glaucoma, first carried out in primates 12 , rabbits 8 , and rats 4, 9, 11 , was recently adapted for use in mice 5, 6, 10 . In these studies, the intracameral injection of polystyrene microbeads, alone or in combination with a viscoelastic material, resulted in IOP elevation leading to subsequent RGC death 6, 10 . However, reflux when the needle is withdrawn from the eye and dislodging of microbeads from the iridocorneal angle are common problems that arise during the procedure. To minimize these drawbacks, magnets have been used to attract the magnetic microbeads to the iridocorneal angle of the eye 4, 9 .
The protocol described here is a modified procedure based on previous studies 9, 10 that uses magnetic microbeads and a handheld magnet 1. Perform procedures in adult C57BL/6 mice. House mice in a standard environment with access to food and water ad libitum. In this paper, use female C57BL/6 mice between 3 and 4.5 months of age. However, this protocol can be adapted to males and mice of different ages, as well as other mouse strains, including transgenic and knockout mice. 2. Measure baseline IOP in awake mice prior to anaesthesia and microbead injection using a calibrated rebound tonometer. Apply one drop of proparacaine hydrochloride on the cornea. 1. Gently restrain the mouse by holding the skin between the ears. Place the mouse on the benchtop so that the animal is comfortable and the eyes are accessible. Hold the tonometer perpendicular to the corneal surface and take at least three sets of ten consecutive readings per eye to obtain an IOP average. The measuring of IOP in awake mice is preferred to bypass anaesthesia-related effects on IOP. Alternatively, IOP can be measured in anesthetised mice after step 3.4.
3. Prepare a stock mouse cocktail anaesthesia mixture composed of 20 mg/ml ketamine, 2 mg/ml xylazine, and 0.4 mg/ml acepromazine. 4. Induce anaesthesia in the mouse by intraperitoneal administration of the cocktail mixture (1 µl/g of body weight). The use of an injectable anaesthetic cocktail is preferred over gas anaesthetics (e.g., isoflurane) because it allows flexibility when handling the mouse head as the animal is not connected to an inhalation mask. In addition, the longer recovery period required with an injectable anaesthetic ensures that microbeads settle at the iridocorneal angle without dislodging back into the anterior chamber. 5. Administer 0.05 mg per kg of body weight of buprenorphine subcutaneously. 6. Treat the eye with a tropicamide eye drop to induce pupil dilation. Due to the small size of the murine anterior chamber, the pupil must be dilated to easily visualize the positioning and advancement of the microneedle during injection. 7. Apply topical ointment on the contralateral eye (un-operated) to avoid drying of the cornea during the procedure. 8. Attach a clean microneedle to the injection assembly of the microsyringe pump. Replace the microneedle after every operation to avoid cross-animal contamination. 9. Person 1: Transfer the anesthetised mouse to the operating platform. Under the microscope, ensure that the pupil is fully dilated and that the ocular muscles are relaxed so that there is no eye movement. The absence of eye movements ensures stability during the injection. Gently wipe the tropicamide eye drop from the eye using absorbent swabs. 10. Person 2: Mix the magnetic microbead solution by pipetting up and down. 11. Using the microsyringe pump, immediately load the microneedle (prepared in section 1) with 1.5 µl of the homogenized magnetic microbead solution (2.4 x 10 6 beads). Ensure that air bubbles are absent at the tip of the microneedle. After the microneedle is loaded, carry out steps 3.12 to 3.13 as quickly as possible so that the magnetic microbead solution remains in a homogeneous suspension. 12. Position the loaded microneedle at a 45° angle, placed anteriorly relative to the limbus. Person 1: support the eye using plastic forceps.
Ensure that the angle between the microneedle and the plastic forceps is approximately 90°. 13. Person 2: With the loaded microneedle, gently puncture the cornea so that the tip of the microneedle enters the anterior chamber. Ensure that the loaded microneedle remains at a 45° angle relative to the limbus during the puncture. Avoid any contact with the lens or the iris. Ensure that the microneedle does not enter the posterior chamber. Person 1: continue to support the eye using plastic forceps. 14. Person 1: Without moving the mouse head, place the magnet beside the eye, opposite to the microneedle tip, to attract the magnetic beads into the anterior chamber and minimize contact of the beads with the inner surface of the cornea. Person 2: Using the microsyringe pump, inject 1.5 µl of the magnetic bead solution into the anterior chamber. The microbead solution is injected over a period of 15 to 30 sec. Person 1: Continue to hold the magnet opposite to the microneedle tip during the entire duration of the injection. 15. Person 2: Once the full volume of beads has been injected, slowly withdraw the microneedle from the eye. Person 1: To avoid reflux of the microbeads, continue to attract the magnetic beads towards the anterior chamber by holding the magnet next to the eye for an additional 30 to 60 sec. 16. Person 1: Using the magnet, attract the beads to the iridocorneal angle. Ensure that the beads form an evenly distributed ring around the circumference of the anterior chamber. During this step, avoid attracting beads to the cornea as they have a tendency to stick to the inner surface of the cornea upon contact. 17. Treat the operated eye with an antibiotic eye drop to minimize the risk of infection. 18. Allow the mouse to recover on a heat pad until fully awake (~3 to 4 hr). Place the mouse so that the operated eye is facing upwards. This positioning will prevent accumulation of the injected beads to the inner surface of the cornea by gravitational pull. In addition, this position will decrease the potential for infection as the operated eye will not be in contact with any bedding and/or other materials that may be present in the cage. In the event that an animal displays any sign of distress, administer additional doses of buprenorphine as needed. 19. Allow mice to recover from the procedure for at least 2 days before taking IOP measurements. Measure IOP as described in 3.2. Monitor IOP at least once a week or more frequently, as needed, and at the same time of the day to minimize circadian-related fluctuations. 20. For IOP measurements, use the contralateral eye from the operated mouse as an internal control. Alternatively, use measurements from intact, non-operated or sham-operated mice as naïve controls.
Assessment of Retinal Ganglion Cell Soma and Axon Survival
2. Perfuse intact, non-operated mice as described in 4.1 and use them as uninjured controls. The use of contralateral eyes from operated mice is not recommended to assess RGC survival because changes in contralateral eyes following injury have been reported 15, 16 and can confound data interpretation. Alternatively, use sham-operated eyes injected with 1.5 µl of BSS as controls. 3. Using microscissors, carefully cut the connective tissue around the eye to isolate it from the eye socket. Separate the optic nerve from the eye by cutting it at the level of the optic nerve head. 4. Using a 30 G needle, make a hole in the cornea to allow penetration of the fixative solution into the eye. Place the eye in 4% PFA and incubate for 1 hr at 4 °C for additional fixation. 5. Place the optic nerve in a solution containing 2% PFA and 2.5% glutaraldehyde in 0.1 M sodium cacodylate (MW: 214 g/mol) and incubate O/ N at 4 °C for additional fixation.
Quantification of RGC Soma Density on Flat-mounted Retinas
Note: The following procedure is adapted from a protocol by Nadal-Nicolas et al. 17 and outlines the quantification of RGCs using an antibody against the brain-specific homeobox/POU domain protein 3A (Brn3a) on retinal flat-mounts. Alternative methods for labeling RGCs can also be used including immunohistochemistry with an antibody against RNA-binding protein with multiple splicing (RBPMS) or retrograde labelling with Fluorogold or DiI.
1. Under a dissecting microscope, remove the anterior part of the eye by making an incision along the entire limbus until the cornea detaches easily. Remove the cornea and lens. Carefully detach the retina from the eye by making cuts along the ora serrata and optic nerve. 2. Prepare a retinal flat-mount by making four small equidistant incisions from the periphery of the retina towards the optic nerve to clearly delineate the four retinal quadrants. Using a small brush, gently remove any remaining vitreous from the retina. The removal of as much vitreous humour as possible is crucial for obtaining a clean and strong immunohistochemical signal. 3. Carefully transfer the retina to a 48-well flat bottom culture plate containing 0.5% Triton X-100 in PBS so that the retina is free-floating. Make sure the ganglion cell layer is facing upwards. 4. Place the culture plate at -70 °C for 15 min. After thawing the retinas, further permeabilize by washing twice in fresh 2% Triton X-100 in PBS. 
Quantification of RGC Axons on Optic Nerve Cross Sections Representative Results
The injection of magnetic microbeads into the anterior chamber of adult mice described in this protocol resulted in a robust and reproducible elevation of IOP. One week after the procedure, IOP increased from 10 ± 0.6 mm Hg (mean ± S.E.M.), the average baseline IOP in contralateral eyes, to 19 ± 0.5 mm Hg in hypertensive eyes (Student's t-test; ***p <0.001, n = 12, Table 1 , Figure 2 ). IOP stabilized thereafter and remained elevated at an average of 20 mm Hg for at least 6 weeks, the longest time-point examined in this study. The average peak IOP in microbeadinjected eyes at 2, 3, and 6 weeks after surgery was 25 mm Hg. The vast majority of treated mice developed sustained high IOP, therefore this protocol does not require a second injection of microbeads.
To assess the time-course of RGC loss in this model, RGC soma were first quantified by immunostaining with Brn3a, a RGC-specific marker 17 . The number of Brn3a-positive cells was quantified on flat-mounted retinas at 1, 2, 3 and 6 weeks after induction of ocular hypertension. Although a significant IOP elevation was detected as early as 1 week after microbead injection, no significant loss of RGC soma was observed within the first 2 weeks of the procedure (Figure 3) . Substantial RGC death (22%), however, was evident at 3 weeks (2,430 ± 67 RGCs/mm 2 , mean ± S.E.M., n = 12) and 6 weeks (2,350 ± 74 RGCs/mm 2 , n = 10) post-induction of ocular hypertension, compared to intact control eyes from unoperated mice (3,141 ± 49 RGCs/mm Dysfunction and degeneration of RGC axons is a cardinal feature of glaucoma. Therefore, axonal loss was examined at 3 and 6 weeks after microbead injection by quantification of RGC axons in optic nerve cross-sections stained with toluidine blue (Figure 4) . A substantial loss of RGC axons (25%) was observed at 3 weeks (28,401 ± 702 axons/nerve, mean ± S.E.M., n = 5) and 6 weeks (29,426 ± 948 axons/ nerve, n = 6) after injection of microbeads compared to intact optic nerves from un-operated eyes (39,467 ± 137 axons/nerve, n = 4) (ANOVA, p <0.001).
Collectively, these data demonstrate that injection of magnetic microbeads into the mouse anterior chamber leads to reproducible and sustained IOP elevation that results in RGC soma and axon degeneration. 6 weeks 12 12 ± 0.5 20 ± 0.6 9 ± 0.7 13 ± 0.5 24 ± 0.6 Table 1 . Elevation of Intraocular Pressure in the Murine Magnetic Microbead Occlusion Model. In awake female C57 BL/6 mice, IOP was measured using a calibrated rebound tonometer. Operated eyes displayed an increase in IOP detected at one week post-surgery that remained elevated for at least six weeks after the procedure. Step-by-step outline of all the procedures performed before, during, and after the surgery. Please click here to view a larger version of this figure.
Ensuring that the number of injected beads is relatively consistent is another critical step to minimize inter-animal variations. Since the microbeads settle at the bottom of the tube, it is necessary to fully homogenize the microbead solution and withdraw the appropriate volume into the microneedle in a timely manner. Injection of fewer beads into the anterior chamber could result in incomplete blockage of the aqueous humour drainage structures, which is likely to result in poor or variable IOP elevation. Of note, although the ultimate purpose of the microbead injection is to elevate IOP, caution should be taken when IOP measurements from awake mice are higher than the peak values reported in this study (~25 mmHg). Extremely high IOPs increase the risk of ischemic damage and may also cause pain to the animal. The elevation of IOP should be considered as one of many factors to assess the success of the surgery. As such, the outcome of the procedure should be gauged based on several parameters including IOP elevation, RGC soma death, and axon loss.
Although the protocol described here results in most microbeads successfully settling at the angle, a potential limitation of this model is that those beads that remain floating in the anterior chamber might interfere with live retinal imaging through the cornea, as well as electrophysiological or behavioral assays which require effective passage of light. Another important aspect to consider when utilizing this microbead occlusion model is that the extent of IOP elevation and subsequent RGC degeneration varies with the age and genetic background of the operated mouse [4] . Therefore, the extent of IOP elevation and the timeline of RGC degeneration will need to be determined for each specific transgenic mouse line and/or age range.
A feature of this model is that elevated IOP results in the gradual loss of RGC death during the first three weeks after microbead injection, and significant RGC death is detected at 3 weeks after the procedure. Hence, this model enables the examination of early and/or subtle changes that occur in this disease, prior to overt RGC soma and axon loss. A significant increase in RGC death was not observed between 3 and 6 weeks after induction of ocular hypertension. In fact, RGC soma and axon loss remained stable at ~22 -25% between 3 and 6 weeks in spite of successful and sustained IOP elevation at these time points. A longer duration of sustained IOP may be required for additional RGC loss to occur in C57BL/6 mice, which appear to be more resistant to RGC damage compared to other mouse strains. 5 Additional modifications to the protocol presented here, including adjustment of bead size and additional injections, might be required to study RGC loss at later time points. Therefore, our protocol is ideal for studies focused on early pathophysiological changes that correlate with modest RGC neurodegeneration which are relevant to onset and early progression in human glaucoma.
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